I kliniske studier med 48 ugers behandling og 24 ugers follow- up svarede sikkerhedsprofilen for Pegasys ved kronisk hepatitis B til sikkerhedsprofilen for kronisk hepatitis C.
In clinical trials of 48 week treatment and 24 weeks follow-up, the safety profile for Pegasys in chronic hepatitis B was similar to that seen in chronic hepatitis C.